The National Cancer Institute (NCI), a component of the U.S. Department of Health and Human Services, has awarded an Indefinite Delivery/Indefinite Quantity (IDIQ) contract valued at up to $548 million to Westat, Inc. for the Cancer Trials Support Unit (CTSU) program. The contract provides broad-based, centralized operational, administrative, regulatory, IT, and logistical support services to enable participation in multi-institutional cancer clinical trials led by NCI-supported organizations. The IDIQ includes six task areas, with some set aside for small businesses, such as awareness/education, protocol writing, and electronic patient-reported outcomes. Initial task orders, valued at over $230 million, cover project kick-off, core CTSU support services, site study setup, and electronic patient data collection in support of the NCI's cancer research mission. Westat, a prominent professional services firm, will perform the contracted work primarily in Potomac, Maryland through the 10-year ordering period ending in 2032.
The CTSU IDIQ was competitively awarded following a pre-solicitation posted in September 2021. The procurement aims to streamline and harmonize support services for NCI-funded cancer clinical trials, building on an earlier IDIQ contract. The scope includes a wide range of operational, administrative, and technical functions to facilitate cancer research studies at multiple sites nationwide and internationally. This contract award demonstrates Westat's extensive experience supporting federal health agencies like the NCI in advancing clinical research and public health initiatives.
Generated 1/14/25, 9:05 AM